HomeTrialNCT07232719
🔬NCT07232719Phase 3RECRUITING

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

Study Summary

The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment250 participants
Primary Completion
Lead SponsorEli Lilly and Company
Data Retrieved2026-04-11 02:55:33.867041+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.